Literature DB >> 31230919

Surgical management of the compromised recurrent laryngeal nerve in thyroid cancer.

Marika D Russell1, Dipti Kamani2, Gregory W Randolph3.   

Abstract

Surgical management of thyroid cancer requires careful consideration of the recurrent laryngeal nerve and its impact on glottic function. Management of the compromised recurrent laryngeal nerve is a complex task, requiring synthesis of multiple elements. The surgeon must have an appreciation for preoperative recurrent laryngeal nerve function, intraoperative anatomic and electromyographic information, disease characteristics, and relevant patient factors. Preoperative clinical evaluation including preoperative laryngoscopy and assessment of recurrent laryngeal nerve risk is essential to formulating a surgical plan and providing appropriate patient counseling. Intraoperative neuromonitoring information has significant implications for surgical management of the injured or invaded recurrent laryngeal nerve and informs strategy with respect to staging of bilateral surgery. Disease characteristics and patient-related factors, including patient preference, must be considered with intraoperative decision-making. Multidisciplinary discussion and patient communication are essential for effective management and successful surgical outcome.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  bilateral surgery; neuromonitoring; recurrent laryngeal nerve; thyroid cancer; thyroidectomy; vocal cord paralysis

Mesh:

Year:  2019        PMID: 31230919     DOI: 10.1016/j.beem.2019.05.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  1 in total

1.  Advanced Differentiated Thyroid Cancer: A Complex Condition Needing a Tailored Approach.

Authors:  Antonio Mario Bulfamante; Eleonora Lori; Maria Irene Bellini; Elisa Bolis; Paolo Lozza; Luca Castellani; Alberto Maria Saibene; Carlotta Pipolo; Emanuela Fuccillo; Cecilia Rosso; Giovanni Felisati; Loredana De Pasquale
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.